Gary P. Fischetti net worth and biography

Gary Fischetti Biography and Net Worth

Director of Anika Therapeutics

Gary P. Fischetti joined the Board of Directors of Anika in April 2023. Mr. Fischetti has extensive experience in the medical device industry, with a focus on strategic planning, organizational change and management responsibilities. Mr. Fischetti retired from active employment in January 2018. Prior to retirement, Mr. Fischetti previously worked for 35 years at Johnson & Johnson (including at its DePuy Synthes orthopedic subsidiaries), in positions of increasing responsibility in multiple businesses, with both domestic and worldwide responsibilities. Mr. Fishcetti served as the company Group Chairman – North American Medical Devices for Johnson & Johnson’s medical device business from 2015 to 2017. He also previously served as the worldwide Company Group Chairman for the DePuy Synthes companies, which included the Joint Reconstruction, Spine, Trauma, CMF, and Power tools businesses. Prior to that, he served as the worldwide Company Group Chairman for all the DePuy Orthopaedic businesses and the Codman franchise, and as the Worldwide President of DePuy Spine from 2005 to 2009. Mr. Fischetti currently serves as the Chairman of the Board for Orchid Orthopedic Solutions. Mr. Fischetti earned his BSBA degree in finance from Villanova University and an M.B.A. from Rutgers University. Mr. Fischetti serves as a member of the Compensation Committee.

What is Gary P. Fischetti's net worth?: The estimated net worth of Gary P. Fischetti is at least $1.07 million as of August 3rd, 2026. Mr. Fischetti owns 53,015 shares of Anika Therapeutics stock worth more than $1,070,108 as of August 6th. This net worth estimate does not reflect any other assets that Mr. Fischetti may own. Learn More about Gary P. Fischetti's net worth.
How do I contact Gary P. Fischetti?: The corporate mailing address for Mr. Fischetti and other Anika Therapeutics executives is 32 WIGGINS AVENUE, BEDFORD MA, 01730. Anika Therapeutics can also be reached via phone at (781) 457-9000 and via email at [email protected]. Learn More on Gary P. Fischetti's contact information.
Has Gary P. Fischetti been buying or selling shares of Anika Therapeutics?: During the last ninety days, Gary P. Fischetti has bought $20,750.00 of Anika Therapeutics stock. Most recently, on Monday, August 3rd, Gary P. Fischetti bought 1,000 shares of Anika Therapeutics stock. The stock was acquired at an average cost of $20.75 per share, with a total value of $20,750.00. Following the completion of the transaction, the director now directly owns 53,015 shares of the company's stock, valued at $1,100,061.25. Learn More on Gary P. Fischetti's trading history.
Who are Anika Therapeutics' active insiders?: Anika Therapeutics' insider roster includes Gary Fischetti (Director), Stephen Griffin (CEO), John Hennemann, III (Director), Raymond Land (Director), and Michael Levitz (CFO). Learn More on Anika Therapeutics' active insiders.
Are insiders buying or selling shares of Anika Therapeutics?: In the last year, Anika Therapeutics insiders bought shares 3 times. They purchased a total of 18,200 shares worth more than $243,988.00. The most recent insider tranaction occured on August, 3rd when Director Gary P Fischetti bought 1,000 shares worth more than $20,750.00. Insiders at Anika Therapeutics own 12.1% of the company. Learn More about insider trades at Anika Therapeutics.
Information on this page was last updated on 8/3/2026.

Gary P. Fischetti Insider Trading History at Anika Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/3/2026	Buy	1,000	$20.75	$20,750.00	53,015

Gary P. Fischetti Buying and Selling Activity at Anika Therapeutics

Anika Therapeutics Company Overview

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $20.19

$19.40

$20.39

50 Day Range

MA: $15.45

$14.20

$20.74

2 Week Range

Now: $20.19

$7.92

$21.11

Volume

119,000 shs

Average Volume

115,492 shs

Market Capitalization

$270.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2